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Abstract: Melatonin is a hormone produced in the pineal gland that controls sleep and circadian
rhythm. Some studies have reported antioxidant and anti-inflammatory effects of melatonin that
could benefit cardiometabolic function; however, there is a lack of evidence to support these assertions.
The aim of this study was to investigate whether melatonin has beneficial effects on arterial stiffness
and mitochondrial deoxyribonucleic acid (DNA) in humans. Methods: This study was designed
as a double-blind randomized controlled study. Thirty-eight healthy women aged 55 years and
older were enrolled. All had insomnia (Pittsburgh Sleep Quality Index (PSQI) ≥ 5), not treated
with any medications, for at least three months before enrollment. Subjects were divided into a
melatonin and a placebo group according to melatonin supplementation. The melatonin group took
2 mg melatonin every night for six weeks. The cardio–ankle vascular index (CAVI) was used as an
indicator of arterial stiffness. After six weeks, CAVI, mitochondrial DNA (mtDNA) copy number in
white blood cells (WBCs), and other metabolic indices, such as homeostasis model assessment of
insulin resistance (HOMA-IR), were checked. Results: Sleep quality index using PSQI was improved
in the melatonin group from a score of 11 to 8 (p = 0.01), but did not change significantly in the
control group. However, there was no significant intergroup difference in PSQI. Systolic blood
pressure (SBP) decreased in the melatonin group from 135 to 128 mmHg (p = 0.015), while remaining
stable in the placebo group. Right CAVI, mitochondrial DNA copy number, and HOMA-IR were not
altered in either group. There were no intergroup differences in CAVI, mtDNA, HOMA-IR, or SBP
between baseline and week six. Conclusions: We found no evidence that melatonin supplementation
improved cardiometabolic parameters like arterial stiffness, mtDNA, or insulin resistance compared
to the placebo between baseline and week six. Sleep quality was improved in the melatonin group.
Further research, including longer-term studies with higher doses of melatonin, is warranted.
Keywords: melatonin; arterial stiffness; mitochondrial DNA; insomnia
1. Introduction
Melatonin (N-acetyl-5-methoxytryptamine) is a neuropeptide hormone derived from
the pineal gland. It conveys signals to distant organs, principally the brain. The main
function of melatonin is to control sleep and circadian rhythm, leading to improved sleep
quality [1]. The potential usefulness of melatonin in cardiometabolic dysfunction is a
popular topic of research, but in vivo evidence for melatonin benefits beyond sleep im-
provement remains scarce. Melatonin can play a role in scavenging free radicals and
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oxidative stress [2]. The indoleamine ring of melatonin and its metabolite detoxify free rad-
icals [3,4]. Biosynthesis of glutathione, a potent antioxidant, is induced by melatonin [4,5].
Melatonin may also play a role in modulating the immune system and cell aging [4,6].
According to a systematic review and meta-analysis by Mohammadi-Sartang et al.,
melatonin supplementation significantly reduces triglycerides and total cholesterol lev-
els, which were more evident at higher doses and longer duration [7]. Some studies
reported that melatonin supplementation could reduce cardiovascular–metabolic diseases,
such as hypertension, diabetes mellitus, and obesity [8–11]. Korkmaz et al. proposed
that antioxidant and anti-inflammatory effects, as well as regulation of the autonomic
nervous system (ANS), might play a role in preventing cardiovascular–metabolic dis-
eases [12]. Acuna-Castroviejo et al. and Leon et al. suggested that stabilization of the
mitochondrial function influences arteriosclerosis, a modifiable risk factor for cardiovascu-
lar diseases, by regulating chronic, low-grade inflammation, oxidative stress, and vascular
endothelial dysfunction [13,14].
We hypothesized that melatonin supplementation could improve cardiometabolic
indices in addition to sleep disturbance. Thus, we aimed to investigate the effects of mela-
tonin supplementation on arterial stiffness and cardiovascular risk factors in women aged
55 years and older with insomnia. We also examined quantitative changes in mitochondrial
deoxyribonucleic acid (DNA) (mtDNA) copy number and the function of ANS before and
after melatonin supplementation.
2. Materials and Methods
2.1. Subject
This study was a single-center, double-blind, placebo-controlled, randomized clinical
trial. All subjects were women over 55 years old with insomnia (Pittsburgh Sleep Qual-
ity Index (PSQI) ≥ 5) [15] who had not taken medication for depression, insomnia, or
tranquilization in the past three months.
Exclusion criteria were as follows: a history of menopausal hormone replacement
therapy; cerebrovascular diseases (including ischemic stroke and cerebral hemorrhage),
cardiovascular diseases (including unstable angina, myocardial infarction, and coronary
revascularization); chronic liver disease (including chronic hepatitis, liver cirrhosis, and
hepatocellular carcinoma); chronic renal disease (including previous chronic kidney disease
and kidney transplantation); malignant neoplasm; any treatment for depression, insomnia,
or tranquilization at least three months before this study; aspartate aminotransferase (AST)
>100 IU/L, alanine aminotransferase (ALT) > 100 IU/L, or creatinine > 1.4 mg/dL.
After the initial screening visit (week zero), subjects were randomly allocated to
two groups: the melatonin and placebo groups. The melatonin group received 2 mg of
prolonged-release melatonin (Circadin 2 mg PR®) (Kuhnil Pharmacy, Seoul, Korea). The
placebo group received a placebo drug with the same appearance as the melatonin pill.
All subjects were instructed to take the pill once a day, two hours before sleep. The study
duration was set to six weeks. After six weeks, a physical examination, questionnaire,
laboratory tests, and arteriosclerosis and ANS function testing were performed. By this
sixth week, subjects brought any remaining medicine and the researcher evaluated the
compliance and side effects of the drug.
The Institutional Review Board at Severance Hospital, Yonsei University College of
Medicine, approved this study (YUHS 4-2016-0418). The study population was recruited
via advertisements posted by the Department of Family Medicine at Severance Hospital,
from October 2017 to October 2018. All subjects provided written informed consent.
2.2. Measurement
We also collected personal lifestyle information (age, marital status, smoking, alco-
hol, exercise, and 15-geriatric depression scale), anthropometric measurements, blood for
laboratory testing (white blood cells (WBC), red blood cells (RBC), hemoglobin, hemat-
ocrit, platelets, AST, ALT, gamma-glutamyl transferase (GGT), creatinine, total cholesterol,
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triglyceride, high-density lipoprotein (HDL), low-density lipoprotein (LDL), glucose, in-
sulin, c-reactive protein (CRP), mitochondrial DNA (mtDNA)), and PSQI at the initial
(week zero) and final (week six) visits. Blood samples were collected after an eight-hour
overnight fasting period. WBC, RBC, hemoglobin, hematocrit, and platelets were measured
using the ADVIA 2120i hematology system (SIMENS Healthcare, Diagnostics, Deerfield,
IL, USA). AST, ALT, GGT, creatinine, total cholesterol, triglyceride, HDL, LDL, glucose,
insulin, and CRP were measured with a Hitachi 7600 analyzer (Hitachi High Technologies
Co., Tokyo, Japan).
We divided alcohol consumption into three categories: “light,” “social,” and “heavy.”
Light drinkers were defined as drinking 1–2 units on any single day or one to two times a
week, social drinkers as drinking 3–4 units on any single day or three times a week, and
heavy drinkers as drinking more than 5 units on any single day or more than five times
a week. All subjects were never-smokers. Exercise was defined as “none,” “sometimes,”
or “often.” “None” was defined as no physical exercise, “sometimes” as physical exercise
performed less than three times a week for 30 min or less than 150 min per week, and
“often” as physical exercise performed more than three times a week for 30 min or more
than 150 min per week.
Height (cm) and weight (kg) were measured, with subjects wearing light indoor
clothing without shoes, using an automated stadiometer (DS-102, DONG SAHN JENIX
Co., Seoul, Korea). Body mass index (BMI, kg/m2) was obtained as weight (kg) divided
by height (m) squared. Waist circumference (cm) was checked at the umbilicus level
when subjects were standing, using an elastic tape measure. Blood pressure (mmHg) was
measured from the right arm, with the subject in a sitting position after he or she had rested
for at least 10 min using an automatic blood pressure monitor (EASY X 800R®, Jawon
Medical, Gyeongsan, Korea).
We estimated insulin resistance using the homeostasis model assessment of insulin
resistance (HOMA-IR) [16]. The formula of HOMA-IR is
HOMA-IR = [{fasting insulin (mU/mL) × fasting glucose (mg/dL)}/405]
2.2.1. Measurement of Arterial Stiffness
Arterial stiffness was measured with a VaSera VS-1000 instrument (Fukuda Denshi Co.
Ltd., Tokyo, Japan) using the cardio–ankle vascular index (CAVI) instrument [17]. Subjects
were examined in the supine position after 5 min of bed rest. Electrocardiogram electrodes
were placed on both wrists and a phonocardiogram was placed at the right sternum border
of the second intercostal space. Cuffs were applied to both upper arms and ankles to detect
brachial and ankle pulse waves. Pulse wave velocity was measured by dividing the pulse
wavelength by the time needed for the pulse wave to propagate from the aorta, through
the femoral artery, to the tibial artery of the ankle. CAVI was calculated as follows
CAVI = a {(2ρ/∆P) × ln (Ps/Pd) PWV2} + b
where Ps = systolic pressure, Pd = d iastolic pressure, ∆P = Ps − Pd, PWV = pulse wave
velocity, ρ = blood density, and a and b are constants.
We recorded mean values for right and left CAVIs.
2.2.2. Measurement of Mitochondrial DNA Copy Number
Blood samples were drawn from the peripheral vein of each participant the morning
after overnight fasting, and were collected in tubes containing ethylenediaminetetraacetic
acid (EDTA)(1 mg/mL). Buffy coats were separated from blood samples by centrifugation
for 10 min at 3000 rpm. The supernatant was carefully discarded by pipetting. DNA was
extracted using a Gentra DNA Extraction Kit (Qiagen, Hilden, Germany). Fluorescence-
based quantitative polymerase chain reaction (qPCR) was used to determine mtDNA
copy number in human leukocytes, according to the nuclear DNA method developed by
Wong et al. [18], with some modifications.
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For the determination of nuclear DNA, the forward primer 5′-GGCTCTGTGAGGGAT-
ATAAAGACA-3′ and reverse primer 5′-CAAACC-ACCCGAGCAACTAATCT-3′ (comple-
mentary to the sequences of the chromosome 1 (Chr1) genome loci on 1q24-25) were used to
amplify a 97-bp product. For analysis of mtDNA, we used NADH dehydrogenase subunit
2 (ND2) gene sequences. The forward primer 5′-CACAGAAGCTGCCATCAAGTA-3′ and
reverse primer 5′-CCGGAGAGTATATTGTTGAAGAG-3′ amplified an 89-bp product. The
quantitative real-time PCR was performed in a Roche LightCycler 480r (Roche Applied
Science, Mannheim, Germany) apparatus using the LightCycler 480 SYBR Green I Master
kit (Roche Applied Science, Mannheim, Germany). DNA (10 ng) was mixed with 10 µL
LightCycler 480 SYBR Green I Master Mix that contained 5 µmol (final concentration
0.4 µM) of forward and reverse primer, with a final volume of 20 µL. PCR reactions were
conducted as follows: initiation at 50 ◦C for 2 min, 95 ◦C for 1 min, 40 cycles of denatura-
tion at 95 ◦C for 15 s, annealing at 60 ◦C for 20 s, extension at 72 ◦C for 15 s, and finally
holding at 25 ◦C. The threshold cycle number (Ct) of the Chr1 gene and the ND2 gene was
determined for each individual qPCR run. ∆Ct [Ct (ND2) − Ct (Chr1)] represents relative
abundance. The quantitative results were expressed as the copy number of mtDNA/cell
by 2 × 2−∆Ct. Each measurement was carried out at least three times and normalized in
each experiment against serial dilutions of a control DNA sample [18,19].
2.2.3. Statistical Analysis
The intended sample of 40 recruited subjects (20 melatonin and 20 placebo) provided a
power of approximately 80%, assuming a significance level of <0.05 between the melatonin
and placebo groups. The dropout rate was expected to be less than 10% based on the
good tolerability of pharmaceuticals. Ultimately, 38 subjects were enrolled. We used
nonparametric statistical analysis because of enrollment numbers. Data are presented as
median (interquartile range (IQR)) or number (percentage). Wilcoxon signed-rank test was
used to compare intragroup differences before and after intervention.
The Mann–Whitney U test was used to calculate the difference between two groups
before and after intervention. We conducted all analyses using SPSS version 23.0 (SPSS
Inc., Chicago, IL, USA). All statistical tests were two-sided, and a value of p < 0.05 was
considered statistically significant.
3. Results
Figure 1 demonstrates the schema of this study and the criteria for inclusion and
exclusion. Fifteen subjects were excluded. Three applicants did not meet the PSQI score.
Six applicants with a history of malignant neoplasms, four applicants on medications
for depression within three months prior to the study’s initiation, and two applicants
who withdrew informed consent due to familial opposition to this study were excluded.
Ultimately, 38 subjects were included in final analyses. After exclusion, all enrolled subjects
fully participated in this study without the discontinuation of medication. One woman
had a side effect of abdominal discomfort that was resolved without intervention. The
medication possession rate was over 80% for all subjects.
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Figure 1. Flow diagram representing the study selection. 
Baseline clinical characteristics of 38 subjects are shown in Table 1. All parameters 
were similar between the placebo and melatonin groups, except total cholesterol and 
insulin levels at baseline. Total cholesterol was higher in the melatonin group than in the 
placebo group (p = 0.031), while insulin was higher in the placebo group than in the 
melatonin supplement group (p = 0.030).  
  
Figure 1. Flow diagram representing the study selection.
Baseline clinical characteristics of 38 subjects are shown in Table 1. All parameters
were similar between the placebo and melatonin groups, except total cholesterol and insulin
levels at baseline. Total cholesterol was higher in the melatonin group than in the placebo
group (p = 0.031), while insulin was higher in the placebo group than in the melatonin
supplement group (p = 0.030).
Table 1. Baseline characteristics according to intervention.
Variables Placebo Melatonin p-Value
Age, years 61.00 (59.00, 65.00) 61.00 (58.00, 71.00) 0.204
Alcohol consumption, N (%) 19 (100) 19 (100) 0.183
Soft 10 (52.63) 5 (26.32)
Social 0 (0) 1 (5.26)
Heavy 9 (47.37) 13 (68.42)
Physical activity, N (%) 19 (100) 19 (100) 0.403
None 2 (10.53) 1 (5.26)
Sometimes 7 (36.84) 4 (21.05)
Often 10 (52.63) 14 (73.69)
MPR, score 97.62 (4.76) 97.62 (4.76) 0.988
PSQI, score 12.00 (6.00) 11.00 (2.50) 0.576
GDS, score 3.00 (6.00) 1.00 (4.00) 0.114
SBP, mmHg 129.00 (28.00) 135.00 (15.00) 0.082
DBP, mmHg 77.00 (13.00) 77.00 (10.00) 0.861
Weight, kg 57.60 (8.80) 62.00 (10.60) 0.274
BMI, kg/m2 23.60 (4.40) 24.90 (3.20) 0.365
Waist, cm 80.00 (15.00) 82.00 (10.00) 0.988
GGT, mg/dL 17.00 (12.00) 16.00 (10.00) 0.781
Cr, mg/dL 0.62 (0.11) 0.68 (0.18) 0.220
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Table 1. Cont.
Variables Placebo Melatonin p-Value
Total cholesterol, mg/dL 178.00 (73.00) 209.00 (40.00) 0.031
TG, mg/dL 106.00 (33.00) 107.00 (67.00) 0.885
HDL cholesterol, mg/dL 51.00 (7.00) 53.00 (19.00) 0.385
LDL cholesterol, mg/dL 101.80 (52.20) 129.80 (51.60) 0.109









CRP, mg/L 0.60 (0.70) 0.60 (0.50) 0.481
Abbreviations: MPR, medication possession rate; PSQI, Pittsburgh Sleep Quality index; GDS, 15-item Geriatric
depression scale; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; Wt, Weight;
BMI, Body Mass Index; GGT, gamma-glutamyl transferase; Cr, creatinine; TG, triglyceride; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; CRP,
C-reactive protein. Alcohol consumption: Light, 1–2 units on any single day or 1–2 times/week; Social, 3–4 units
on any single day or 3 times/week; Heavy, more than 5 units on any single day or more than 5 times/week.
Physical activity: Sometimes, less than three times a week for 30 min or less than 150 min per week; Often,
more than three times a week for 30 min or more than 150 min per week. All values are presented as median
(interquartile range) or number (percentage). p-values were derived from the chi-square test for smoking, alcohol,
and exercise. p-values were derived from the Mann–Whitney U test for age, MPR, PSQI, GDS, SBP, DBP, weight,
BMI, waist, GGT, Cr, total cholesterol, TG, HDL, LDL, glucose, insulin, and CRP.
Table 2 shows changes in cardiovascular parameters, sleep index, insulin resistance,
and mtDNA. We compared intra- and inter-group differences in CAVI, mtDNA, HOMA-IR,
PSQI, and SBP between the baseline and week six in the placebo and melatonin groups.
Sleep quality index improved in the melatonin group (p = 0.010), but did not change
significantly in the control group (p = 0.230). However, there were no significant intergroup
differences between the melatonin and placebo groups (p = 0.158). SBP was reduced from
135 to 128 mmHg in the melatonin group (p = 0.015), while SBP in the placebo group was
not altered (p = 0.153). Right CAVI, mtDNA copy number, and HOMA-IR were not affected
in either group. Left CAVI was elevated in the placebo group. There were no intergroup
differences in CAVI, mtDNA, HOMA-IR, or SBP from the baseline to week six between the
placebo and melatonin groups.
Table 2. Changes in cardiovascular parameters, sleep index, insulin resistance, and mitochondrial DNA.
Placebo (n = 19) Melatonin (n = 19)
Variable Baseline 6 Weeks Baseline 6 Weeks IntergroupDifference
Median (IQR) p-Value a Median (IQR) p-Value a p-Value b
RCAVI 8.10 (1.25) 7.80 (0.12) 0.587 8.05 (2.00) 7.90 (1.83) 0.163 0.582
LCAVI 8.15 (1.78) 8.20 (1.27) 0.025 7.60 (1.28) 7.45 (1.30) 0.095 0.813







HOMA-IR 1.68 (1.29) 2.01 (1.15) 0.260 1.04 (0.78) 1.17 (0.84) 0.573 0.661
PSQI, score 12 (6) 9 (6) 0.230 11 (3) 8 (5) 0.010 0.158
SBP, mmHg 129 (28) 121 (15) 0.153 135 (15) 128 (16) 0.015 0.781
Abbreviations: IQR, interquartile range; RCAVI, Right cardio–ankle vascular index; LCAVI, Left cardio–ankle vascular index; mtDNA,
mitochondrial DNA copy number; HOMA-IR, Homeostasis model assessment of insulin resistance; PSQI, Pittsburgh Sleep Quality index;
SBP, systolic blood pressure. a p values were calculated by Wilcoxon signed-rank test for intragroup differences before and after intervention.
b p values for intergroup difference were calculated by the Mann–Whitney U test for the difference between two groups before and
after intervention.
Table 3 shows other metabolic indices. Intra- and inter-group differences in geriatric
depression scale, pulse rate, BMI, WBC, hemoglobin, ALT, GGT, creatinine, total cholesterol,
LDL cholesterol, glucose, CRP, and heart rate variability indices were demonstrated. Pulse
rate was higher in the melatonin group (p = 0.021), but not significantly changed in the
placebo group (p = 0.420). Intergroup difference was observed between the two groups at
the baseline and week six (p = 0.019). Additionally, hemoglobin changes were not significant
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in intragroup comparisons but were significantly different in intergroup comparisons
(p = 0.036). There were no intra- and inter-group differences in other parameters (all
p > 0.05).
Table 3. Comparison of other metabolic indices.
Placebo (n = 19) Melatonin (n = 19)
Variable Baseline 6 Weeks Baseline 6 Weeks IntergroupDifference
Median (IQR) p-Value a Median (IQR) p-Value a p-Value b
GDS, score 3 (6) 1 (3) 0.001 1 (4) 1 (2) 0.076 0.165
PR 71 (12) 71 (11) 0.420 72 (12) 77 (8) 0.021 0.019
BMI, kg/m2 23.60 (4.40) 23.90 (5.00) 0.635 24.90 (3.20) 25.10 (2.70) 0.793 0.558
WBC, 103/µL 6010 (930) 5780 (1540) 0.747 4980 (1440) 5690 (1350) 0.083 0.293
Hb, g/dL 13.10 (1.30) 13.10 (1.40) 0.266 13.30 (1.30) 13.40 (1.30) 0.081 0.036
ALT, IU/L 17 (9) 17 (11) 0.588 20 (8) 19 (11) 0.686 0.500
GGT, mg/dL 17 (12) 16 (12) 0.230 16 (10) 16 (9) 0.152 0.054
Cr, mg/dL 0.62 (0.11) 0.63 (0.04) 0.601 0.68 (0.18) 0.73 (0.17) 0.247 0.640
T.chol, mg/dL 178 (73) 190 (61) 0.170 209 (40) 215 (43) 0.421 0.492
LDL, mg/dL 101.8 (52.2) 113.8 (47.6) 0.546 129.8 (51.6) 139.0 (57.2) 0.702 0.872
Glucose, mg/dL 96 (8) 99 (15) 0.221 98 (10) 97 (18) 0.635 0.169








VLF 5.07 (0.96) 5.19 (1.20) 0.573 5.45 (1.31) 5.54 (1.19) 0.777 0.671
LF 4.40 (1.19) 4.24 (1.51) 0.334 4.86 (0.97) 4.47 (0.78) 0.557 0.153
HF 4.64 (1.75) 4.73 (1.75) 0.778 4.83 (1.61) 4.89 (0.89) 0.945 0.832
TP 6.11 (1.07) 6.09 (1.12) 0.324 6.28 (0.69) 6.25 (0.76) 0.586 0.346
LF/HF ratio 0.84 (0.78) 0.78 (2.16) 0.198 0.90 (1.17) 0.86 (1.39) 0.472 0.693
Abbreviations: IQR, interquartile range; MPR, medication possession rate; GDS, 15-item Geriatric depression scale; BMI, body mass index;
DBP, diastolic blood pressure, TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CRP, C-reactive protein;
SDNN, standard deviation of all normal-to-normal interval; VLF, very low frequency; HF, high frequency; LF, low frequency; TP, total
power. a p values were calculated by Wilcoxon signed-rank test for intragroup differences before and after intervention. b p values for
intergroup difference were calculated by Mann–Whitney U test for the difference between two groups before and after intervention.
4. Discussion
This double-blind, randomized, placebo-controlled study showed that a six-week
melatonin intervention improved sleep quality and decreased SBP levels in women aged
55 years and older with insomnia. However, melatonin supplementation did not improve
arteriosclerotic markers, such as CAVI, or insulin resistance.
Lemoine reported that prolonged-release melatonin significantly improved quality of
sleep and morning alertness in women with primary insomnia [20]. Scheer demonstrated
that regular melatonin supplementation at bedtime reduced nocturnal blood pressure in
men with essential hypertension [21]. According to Możdżanstudy [22], the blood-pressure-
lowering effects of melatonin are statistically significant in individuals with type 2 diabetes
with non-dipper type hypertension. These findings are consistent with the current study,
in which melatonin improved sleep quality and reduced SBP.
Tengattini suggested that several cardiac conditions, such as cardiac ischemia/reperfusion,
atherosclerosis, and hypertension, were a consequence of free radical damage and processes
involving an inflammatory response [23]. The beneficial effects of melatonin administra-
tion against pro-inflammatory conditions may be directly and indirectly due to its free
radical-scavenging activities and anti-oxidative function. When exogenously administered,
melatonin is quickly distributed throughout the organism, where it moves into the intra-
cellular area, and is accumulated in the mitochondria. Mitochondria are a major site of
free radical and oxidative stress generation. Melatonin protects against mitochondrial
dysfunction through the prevention of mitochondrial membrane depolarization by reactive
oxygen species (ROS) [24]. Melatonin can serve as a beneficial agent promoting some
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clinical conditions related to mitochondrial function. Obayashi [25] and Lee [26] supported
the hypothesis that urinary-excreted melatonin metabolite levels are inversely associated
with arterial stiffness. Initially, we hypothesized that melatonin would improve CAVI as
an auxiliary indicator for arterial stiffness [27,28], mitochondrial DNA, and HOMA-IR, as
well as the other cardiometabolic markers beyond its effects on insomnia.
Arterial stiffness, insulin resistance, and mtDNA copy number were not improved
after six weeks of supplementation with melatonin in this study. This is inconsistent with
previous studies and our hypothesis. Unlike the abovementioned studies, this study was
designed as a randomized, placebo-controlled, double-blinded trial in a hospital setting. It
is possible that, compared to observational studies or non-randomized, controlled, clinical
trials, this randomized, controlled, clinical study is more stringently designed and better
reflects the pharmaceutical effects of melatonin in human subjects.
In part, the origin of these differences may be randomization and allocation at baseline
in relation to the small sample size. Six subjects (31.6%) in the placebo group and eight
subjects (42.1%) in the melatonin group had dyslipidemia and took anti-dyslipidemic
medications. Six subjects (31.6%) in the placebo group and one subject (5.3%) in the
melatonin group had hypertension. The small sample size may have contributed to this
null association between melatonin supplements and clinical outcomes.
Our study has some limitations that should be considered when interpreting these
results. Six weeks may be an insufficient duration to observe the effects of improving
arterial stiffness, mtDNA, and insulin resistance. Few studies with a randomized controlled
design have investigated the duration of melatonin use and cardiometabolic function. The
follow-up duration of most previous studies on melatonin’s sleep improvement effects
was less than four weeks [11,20,29–31]. In the few studies that have investigated its
cardiometabolic effects, the follow-up did not exceed six weeks. Thus, we considered a
follow-up duration of six weeks to be appropriate for investigating the cardiometabolic
effects of melatonin. Due to the lack of evidence regarding long-term use, we set the
treatment period to six weeks. It is possible that longer-term use could reveal further effects
that were not observed in this study, and further research is warranted. Additionally, a
prolonged-release 2 mg melatonin dose might have been too low to reverse arterial stiffness.
We could not escalate the dose because of dose restrictions related to Circadin® 2 mg and
its approval by the Korean Ministry of Food and Drug Safety for melatonin. Future
research should investigate higher melatonin doses and their effects on cardiovascular
factors and mitochondrial function. In addition, urine metabolites were not measured
before and after the experiment to determine the concentration of active melatonin in
the human body. Circulating melatonin is inactivated in the liver where it is converted
to 6-hydroxymelatonin and then conjugated with sulfate or glucuronide and excreted in
urine. Circulating melatonin levels have been reported to decrease with physiological
aging [32]. If the amount of active melatonin was measured, we could more accurately
compare the effects of melatonin on cardiometabolic function. Finally, all subjects were
generally healthy. Therefore, caution is needed when generalizing these results to people
with chronic severe illness.
This study has several advantages over previous research. This study was carefully
designed as a randomized, placebo-controlled, double-blinded trial that enrolled 38 women.
Few randomized, controlled, double-blind trials of melatonin supplements have been
conducted. Among them, most studies enrolled less than 20 participants. Population size
is important because it affects statistical power. While the number of participants in this
study was small, it was larger than previous studies.
5. Conclusions
Consistent with previous studies, we have shown that melatonin supplementation
for six weeks improves sleep quality. However, it was not proven that melatonin could
improve cardiometabolic parameters such as arterial stiffness, mtDNA, or insulin resistance
in this human study. In part, this null association between melatonin supplementation
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and cardiometabolic indices might be due to the low dose or short duration of melatonin
supplementation. Further investigation with a long-term intervention at a higher dose
of melatonin is needed to obtain a clear understanding of the cardiometabolic effects of
melatonin treatment.
Author Contributions: Conceptualization, D.-C.L., Y.K.; methodology, D.-C.L. and Y.K.; software,
D.-C.L.; validation, Y.K. and D.-C.L.; formal analysis, Y.K. and H.-T.K.; statistical analysis, Y.K.; inves-
tigation, Y.K.; resources, Y.K., H.-T.K. and D.-C.L.; data curation, Y.K. and H.-T.K.; writing—original
draft preparation, Y.K.; writing—review and editing, H.-T.K., Y.K., and D.-C.L.; visualization, H.-T.K.
and D.-C.L.; supervision, H.-T.K. and D.-C.L.; project administration, D.-C.L.; funding acquisition,
D.-C.L. All authors have read and agreed to the published version of the manuscript.
Funding: This work was supported by Kuhnil Pharmacy (Seoul, Korea) grant number [YUHS 4-
2016-0418] and APC was funded by Kuhnil Pharmacy. The content of this manuscript is solely the
responsibility of the authors and does not necessarily represent the official views of Kuhnil Pharmacy.
The funding bodies were not involved in the design of the study, collection and analysis of data, or
manuscript preparation.
Institutional Review Board Statement: The study was conducted according to the guidelines of the
Declaration of Helsinki, and approved by the Institutional Review Board of Severance Hospital in
the Republic of Korea (protocol code: YUHS 4-2016-0418 and date of approval: 23 July 2017).
Informed Consent Statement: Informed consent was obtained from all subjects involved in the
study. Written informed consent has been obtained from the patients to publish this paper.
Data Availability Statement: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Pandi-Perumal, S.R.; Srinivasan, V.; Spence, D.W.; Cardinali, D.P. Role of the melatonin system in the control of sleep. CNS Drugs
2007, 21, 995–1018. [CrossRef] [PubMed]
2. Esposito, E.; Cuzzocrea, S. Antiinflammatory activity of melatonin in central nervous system. Curr. Neuropharmacol. 2010, 8,
228–242. [CrossRef] [PubMed]
3. Reiter, R.J.; Tan, D.; Terron, M.P.; Flores, L.J.; Czarnocki, Z. Melatonin and its metabolites: New findings regarding their production
and their radical scavenging actions. Acta Biochim. Pol. Engl. Ed. 2007, 54, 1–9. [CrossRef]
4. Carpentieri, A.; De Barboza, G.D.; Areco, V.; López, M.P.; De Talamoni, N.T. New perspectives in melatonin uses. Pharmacol. Res.
2012, 65, 437–444. [CrossRef]
5. Reiter, R.J.; Tan, D.; Mayo, J.C.; Sainz, R.M.; Leon, J.; Czarnocki, Z. Melatonin as an antioxidant: Biochemical mechanisms and
pathophysiological implications in humans. Acta Biochim. Pol. Engl. Ed. 2003, 50, 1129–1146. [CrossRef]
6. Cardinali, D.P.; Cano, P.; Jiménez-Ortega, V.; Esquifino, A.I. Melatonin and the metabolic syndrome: Physiopathologic and
therapeutical implications. Neuroendocrinology 2011, 93, 133–142. [CrossRef]
7. Mohammadi-Sartang, M.; Ghorbani, M.; Mazloom, Z. Effects of melatonin supplementation on blood lipid concentrations: A
systematic review and meta-analysis of randomized controlled trials. Clin. Nutr. 2018, 37, 1943–1954. [CrossRef] [PubMed]
8. Koziróg, M.; Poliwczak, A.R.; Duchnowicz, P.; Koter-Michalak, M.; Sikora, J.; Broncel, M. Melatonin treatment improves blood
pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J. Pineal Res. 2011, 50, 261–266.
[CrossRef] [PubMed]
9. Nduhirabandi, F.; du Toit, E.F.; Lochner, A. Melatonin and the metabolic syndrome: A tool for effective therapy in obesity-
associated abnormalities? Acta Physiol. 2012, 205, 209–223. [CrossRef]
10. Agil, A.; Rosado, I.; Ruiz, R.; Figueroa, A.; Zen, N.; Fernández-Vázquez, G. Melatonin improves glucose homeostasis in young
Zucker diabetic fatty rats. J. Pineal Res. 2012, 52, 203–210. [CrossRef]
11. Grossman, E.; Laudon, M.; Zisapel, N. Effect of melatonin on nocturnal blood pressure: Meta-analysis of randomized controlled
trials. Vasc. Health Risk Manag. 2011, 7, 577–584.
12. Korkmaz, A.; Topal, T.; Tan, D.-X.; Reiter, R.J. Role of melatonin in metabolic regulation. Rev. Endocr. Metab. Disord. 2009, 10,
261–270. [CrossRef]
13. Acuna-Castroviejo, D.; Escames, G.; Rodriguez, M.I.; Lopez, L.C. Melatonin role in the mitochondrial function. Front. Biosci. 2007,
12, 947–963. [CrossRef]
14. Leon, J.; Acuña-Castroviejo, D.; Sainz, R.M.; Mayo, J.C.; Tan, D.-X.; Reiter, R.J. Melatonin and mitochondrial function. Life Sci.
2004, 75, 765–790. [CrossRef]
15. Buysse, D.J.; Reynolds, I.I.I.C.F.; Monk, T.H.; Berman, S.R.; Kupfer, D.J. The Pittsburgh Sleep Quality Index: A new instrument for
psychiatric practice and research. Psychiatry Res. 1989, 28, 193–213. [CrossRef]
Int. J. Environ. Res. Public Health 2021, 18, 2561 10 of 10
16. Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turner, R.C. Homeostasis model assessment: Insulin
resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28, 412–429.
[CrossRef] [PubMed]
17. Shirai, K.; Utino, J.; Otsuka, K.; Takata, M. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle
vascular index (CAVI). J. Atheroscler. Thromb. 2006, 13, 101–107. [CrossRef] [PubMed]
18. Wong, A.; Cortopassi, G. Reproducible Quantitative PCR of Mitochondrial and Nuclear DNA Copy Number Using the LightCy-
cler™. In Mitochondrial DNA; Springer: Amsterdam, The Netherlands, 2002; pp. 129–138.
19. Livak, K.; Schmittgen, T. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T))
Method. Methods 2001, 25, 402–408. [CrossRef] [PubMed]
20. Lemoine, P.; Nir, T.; Laudon, M.; Zisapel, N. Prolonged-release melatonin improves sleep quality and morning alertness in
insomnia patients aged 55 years and older and has no withdrawal effects. J. Sleep Res. 2007, 16, 372–380. [CrossRef] [PubMed]
21. Scheer, F.A.; Van Montfrans, G.A.; van Someren, E.J.; Mairuhu, G.; Buijs, R.M. Daily nighttime melatonin reduces blood pressure
in male patients with essential hypertension. Hypertension 2004, 43, 192–197. [CrossRef]
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